Search

Displaying results 3251 - 3260 of 8171 in total
  1. Drug

    Gliclazide

    go.drugbank.com/drugs/DB01120
    ApprovedInvestigational

    Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea, 1-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
  2. Drug

    Ferric pyrophosphate citrate

    go.drugbank.com/drugs/DB13995
    Approved

    Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.

  3. Drug

    Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB10076
    Approved

    *H. influenzae* is a Gram-negative coccobacillus that can cause infections including sepsis and meningitis.

  4. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    As it is injectable, it can be used perioperatively when patients are unable to take oral medications.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide
  5. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.

  7. Drug

    Bertilimumab

    go.drugbank.com/drugs/DB05429
    Investigational

    Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.

  8. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051]

  9. Drug

    Efinaconazole

    go.drugbank.com/drugs/DB09040
    ApprovedInvestigational

    Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North ...

  10. Drug

    Ambrosia artemisiifolia pollen

    go.drugbank.com/drugs/DB10385
    Approved

    Ambrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.